Federal grants to Trethera Corp
Trethera Corp in Sherman Oaks, California received $10.8 million in federal grants from fiscal 2021 to 2025, across 10 awards. Its largest program was Allergy and Infectious Diseases Research, with $4.3 million. In fiscal 2025 it was awarded $5.1 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$10.8 million
- Awards10
- Awarded in FY 2025$5.1 million
- Largest award$2.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 0 | $0 |
| FY 2022 | 1 | $368,195 |
| FY 2023 | 4 | $2.4 million |
| FY 2024 | 5 | $3.0 million |
| FY 2025 | 6 | $5.1 million |
Programs that fund Trethera Corp
| Program | Awards | Amount |
|---|---|---|
| Allergy and Infectious Diseases Research | 4 | $4.3 million |
| Cancer Treatment Research | 3 | $3.6 million |
| Vision Research | 1 | $1.6 million |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 2 | $1.3 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 10 | $10.8 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through ind enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM) - project summary acute disseminated encephalomyelitis (ADEM) is an autoimmune disease that can pres | Allergy and Infectious Diseases Research | July 2, 2024 | $2.0 million |
| Development of a novel, targeted small molecule inhibitor of the nucleotide salvage pathway to treat underserved tumor types - project summary trethera, a clinical stage biopharmaceutical company, has developed a small molecule drug, TRE-515, to target the nucleoside salvage pathway via a key rate-l | Cancer Treatment Research | May 30, 2023 | $2.0 million |
| Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway to treat optic neuritis - project summary optic neuritis (ON) is an acute autoimmune disease caused by immune attack on the myelin that protects the optic nerve leading to vision loss. Steroid treatments acce | Vision Research | September 15, 2022 | $1.6 million |
| Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumors - project summary trethera, a clinical stage biopharmaceutical company, has developed a first-in-class small mole | Cancer Treatment Research | August 18, 2025 | $1.1 million |
| Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway to treat systemic lupus erythematosus - project summary systemic lupus erythematosus (SLE) is a challenging disease in need of new treatment options. Sle is a chronic, debilitating, heterogenous autoimmune di | Allergy and Infectious Diseases Research | August 7, 2025 | $994,978 |
| Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway to treat crohn's disease - project summary crohn’s disease (CD) is a chronic autoimmune disease in which cells of the immune system attack gut tissue leading to diarrhea, fatigue, weight loss, fistulas, and a | Diabetes, Digestive, and Kidney Diseases Extramural Research | September 2, 2025 | $905,290 |
| Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway to treat systemic lupus erythematosus - project summary lupus is a chronic, systemic autoimmune disease in which cells of the immune system attack organ systems throughout the body including the kidneys, brai | Allergy and Infectious Diseases Research | June 21, 2023 | $610,850 |
| Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway to treat acute disseminated encephalomyelitis (ADEM) - project summary acute disseminated encephalomyelitis (ADEM) is an acute autoimmune disease that can present with fever and ataxia as well as loss of cons | Allergy and Infectious Diseases Research | July 31, 2023 | $601,603 |
| Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through murine studies to enable further clinical advancement in non-small-cell lung cancer - project summary non-small cell lung cancer (NSCLC) is the most common type of lung cancer, the leading cause of ca | Cancer Treatment Research | September 5, 2025 | $406,500 |
| Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway to treat crohn's disease - project summary crohn’s disease (CD) is a chronic autoimmune disease in which cells of the immune system attack gut tissue leading to diarrhea, fatigue, pain, and weight loss. Cd af | Diabetes, Digestive, and Kidney Diseases Extramural Research | September 19, 2023 | $395,119 |
Questions people ask
How much federal grant money does Trethera Corp get?
$10.8 million in 10 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Trethera Corp the most?
The Department of Health and Human Services, with $10.8 million in 10 awards.
What is Trethera Corp's largest federal grant?
$2.0 million under Allergy and Infectious Diseases Research, with its first action in the period on July 2, 2024. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Trethera Corp?
Its largest are Allergy and Infectious Diseases Research, Cancer Treatment Research and Vision Research.
Largest federal grant recipients in California · Federal grants in California